News | May 14, 2024
Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Executes the first project for developing and manufacturing a novel anticancer mAb
To accelerate the development of next-generation radioconjugates to treat cancer
Sen spent a decade with Biocon and held various key roles,
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Total transaction value of the divestment is Rs. 3,660 million
Subscribe To Our Newsletter & Stay Updated
